Advocacy intelligence hub — real-time data for patient organizations
Sodium Phenylbutyrate: FDA approved
Adjunctive therapy in the chronic managment of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Sodium Phenylbutyrate
ENDO USA, Inc.
Sodium Phenylbutyrate
(SODIUM PHENYLBUTYRATE TABLETS, 500 MG)Orphan drugENDO USA, Inc.